Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunovant Inc (NQ: IMVT ) 30.81 -0.09 (-0.29%) Streaming Delayed Price Updated: 11:35 AM EDT, Sep 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Immunovant Inc < Previous 1 2 3 4 5 Next > After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay May 30, 2024 Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. Via Investor's Business Daily IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024 May 29, 2024 IMVT stock results show that Immunovant missed analyst estimates for earnings per share the fourth quarter of 2024. Via InvestorPlace 12 Health Care Stocks Moving In Wednesday's After-Market Session May 29, 2024 Via Benzinga Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study May 29, 2024 Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. Via Benzinga Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session May 29, 2024 Via Benzinga Recap: Immunovant Q3 Earnings February 12, 2024 Via Benzinga Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday May 29, 2024 Via Benzinga Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump May 29, 2024 The company says it's still running additional testing of the drug, calling the results "positive." Via Investor's Business Daily Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich March 25, 2024 Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. Via InvestorPlace Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results March 21, 2024 Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart. Via Investor's Business Daily Argenx Dives On Autoimmune Therapy Failure December 20, 2023 A treatment for a skin-blistering condition failed to beat a placebo. Via Investor's Business Daily Analyst Ratings for Immunovant December 01, 2023 Via Benzinga Where Immunovant Stands With Analysts November 15, 2023 Via Benzinga Recap: Immunovant Q2 Earnings November 09, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session March 21, 2024 Via Benzinga 3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 February 26, 2024 Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. Via InvestorPlace 7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 February 06, 2024 Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge. Via InvestorPlace 3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024 January 19, 2024 Analyst ratings tell investors which stocks institutional investors like, here are three top-rated Russell 2000 stocks to consider in 2024 Via InvestorPlace 5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond January 15, 2024 These five biotech companies could have a lot of room to run. Via The Motley Fool Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review December 22, 2023 Despite a Wednesday tumble, the major indexes are right at 2023 highs. Via Investor's Business Daily Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session December 21, 2023 Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. Via Benzinga Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off December 21, 2023 Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday. Via Investor's Business Daily Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% December 21, 2023 Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in Via Benzinga Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday December 21, 2023 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session December 21, 2023 U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday. Via Benzinga Topics Stocks Exposures US Equities Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease December 20, 2023 From Roivant Sciences Via GlobeNewswire Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session December 20, 2023 Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. Via Benzinga FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session December 20, 2023 U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review December 01, 2023 Software earnings were strong, while the Fed is shifting toward rate cuts. Via Investor's Business Daily Topics Economy Stocks Exposures Interest Rates US Equities Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential November 28, 2023 From Roivant Sciences Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
